Bausch Health Companies Inc. (TSE:BHC - Free Report) - Equities researchers at Zacks Research decreased their Q2 2026 earnings per share (EPS) estimates for Bausch Health Companies in a research note issued to investors on Wednesday, May 21st. Zacks Research analyst R. Department now forecasts that the company will earn $1.34 per share for the quarter, down from their previous forecast of $1.59. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2026 earnings at $1.55 EPS.
Bausch Health Companies Stock Performance
Bausch Health Companies stock traded down C$0.05 during trading hours on Friday, reaching C$6.30. 273,888 shares of the stock were exchanged, compared to its average volume of 343,360. Bausch Health Companies has a 52-week low of C$5.45 and a 52-week high of C$13.74. The stock has a market cap of C$1.64 billion, a P/E ratio of -9.22, a P/E/G ratio of 0.21 and a beta of 0.77. The company has a debt-to-equity ratio of -1,831.94, a quick ratio of 0.58 and a current ratio of 1.19. The firm's 50 day moving average is C$7.30 and its 200 day moving average is C$9.57.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Featured Stories
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
